Electrocore (ECOR) AI Stock Analysis

• Market Cap: $37.77M
• Dividend Yield: N/A
• Average Volume (3M): 135.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 41.54%
• EPS Growth: 42.59%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Devices
• EPS (TTM): -0.47
• Shares Outstanding: 7,420,618
• 10 Day Avg. Volume: 76,804
• 30 Day Avg. Volume: 135,567
• PEG Ratio: -0.11
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.10
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 0.01
• Enterprise Value/Gross Profit: 0.06
• Enterprise Value/Ebitda: -0.03
• 1Y Price Target: $18.50
• Price Target Upside: 263.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 58 Neutral
• Price Target: $5.50 ▲(8.06%Upside)

Electrocore shows potential through impressive revenue growth and strategic initiatives like the NeuroMetrix merger. However, significant challenges remain, such as profitability issues, high liabilities, and negative cash flows, impacting the overall financial health and stock attractiveness.

Positive Factors

Acquisition Impact

The acquisition increases the company’s total addressable market and diversifies its portfolio of non-invasive wellness products, which should be additive to growth.

Distribution Expansion

ECOR can leverage its established distribution platform to accelerate prescriptions of the Quell technology without added operating expenses.

Market Opportunity

The VA hospital system represents a significant opportunity for expansion of Quell products as it is currently being sold in only two hospitals.

Negative Factors

Price Target Revision

Analyst is lowering estimates and the 12-month price target to $12 from $25 due to quarterly TAC-STIM sales variability and updated outlook on Quell's commercial pathway.

Revenue Guidance

Lower-than-expected 2025 revenue guidance introduced, with the company expecting $30M, representing 19.1% y/y growth, below prior consensus and estimates.

Electrocore Business Overview & Revenue Model

Company Description

Electrocore (ECOR) is a medical technology company focused on developing and commercializing innovative therapies for treating a range of neurological and immunological disorders. The company specializes in non-invasive vagus nerve stimulation (nVNS) technology that offers patients an alternative treatment option for conditions such as migraine and cluster headaches. Electrocore's flagship product, gammaCore, is a handheld device designed to deliver nVNS therapy, providing a portable, drug-free solution for patients.

How the Company Makes Money

Electrocore generates revenue primarily through the sale of its gammaCore device and related accessories. The company sells its products directly to healthcare providers, patients, and through strategic partnerships with distributors. Revenue is also generated from commercial payers and government reimbursement programs, which cover the cost of the gammaCore device for eligible patients. Additionally, Electrocore may engage in licensing agreements or collaborations to expand the application of its nVNS technology to other therapeutic areas, thus potentially creating additional revenue streams. Partnerships with healthcare organizations and participation in clinical trials further support its business model by validating the efficacy of its products and facilitating market access.

Electrocore Financial Statement Overview

Summary

Electrocore has shown significant revenue growth, indicating a strong market for its products. However, the company struggles with profitability and relies on external financing due to negative operating cash flows and high liabilities.

Income Statement

Electrocore has shown a consistent growth in revenue over the years, with a notable increase from $2.39 million in 2019 to $25.18 million in 2024. However, the company is still facing significant profitability challenges, as evidenced by negative net income and EBIT margins across the years. Despite the revenue growth, the company has not yet achieved positive net profit margins or EBIT margins, indicating that cost control and operational efficiency are areas for improvement.

Balance Sheet

The company's balance sheet reflects a relatively high level of liabilities compared to its equity, with a debt-to-equity ratio of 0.55 in 2024. Stockholders' equity has remained relatively stable from 2023 to 2024, but the equity ratio has decreased due to a rise in total liabilities. The company maintains a reasonable cash position, which provides some liquidity cushion. However, the consistent negative net income impacts the overall return on equity.

Cash Flow

Electrocore's cash flow situation shows significant negative operating cash flows, indicating that the company has not yet reached a sustainable cash-generating position from its core operations. Free cash flow has improved slightly but remains negative, suggesting that the company is still reliant on external financing to support its operations and growth. The operating cash flow to net income ratio is poor due to persistent negative earnings.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
26.46M	25.18M	16.03M	8.59M	5.45M	3.50M
	Gross Profit
22.55M	21.40M	13.23M	6.98M	4.07M	1.76M
	EBIT
-12.13M	-12.16M	-18.80M	-22.87M	-20.04M	-24.28M
	EBITDA
-11.35M	-10.90M	-17.76M	-22.33M	-19.66M	-24.18M
	Net Income Common Stockholders
-12.23M	-11.89M	-18.83M	-22.16M	-17.22M	-23.51M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.76M	11.97M	10.33M	17.71M	34.69M	22.63M
	Total Assets
16.04M	20.47M	16.10M	24.76M	42.83M	31.52M
	Total Debt
4.18M	4.14M	626.00K	699.00K	760.87K	2.99M
	Net Debt
407.00K	686.00K	-9.71M	-17.01M	-33.93M	-1.25M
	Total Liabilities
11.68M	12.93M	8.66M	7.67M	6.18M	7.87M
	Stockholders Equity
4.37M	7.54M	7.44M	17.09M	36.65M	23.64M
Cash Flow		Free Cash Flow
-8.74M	-6.95M	-14.87M	-16.64M	-13.63M	-20.10M
	Operating Cash Flow
-8.74M	-6.95M	-14.67M	-16.64M	-13.63M	-20.10M
	Investing Cash Flow
-4.02M	-8.52M	-206.00K	0.00	18.22M	-7.96M
	Financing Cash Flow
8.62M	8.44M	7.49M	0.00	25.68M	18.95M

Electrocore Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECOR, the sentiment is Negative. The current price of 5.09 is below the 20-day moving average (MA) of 5.24, below the 50-day MA of 5.77, and below the 200-day MA of 10.24, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 41.55 is Neutral, neither overbought nor oversold. The STOCH value of 48.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECOR.

Electrocore Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICAD	60 Neutral	$101.09M	―	-16.53%	―	-4.15%	3.49%
TELA	60 Neutral	$67.24M	―	-267.29%	―	12.78%	15.53%
ECOR	58 Neutral	$37.77M	―	-276.15%	―	41.54%	42.59%
NVNO	58 Neutral	$76.11M	―	-52.88%	―	―	29.64%
APYX	56 Neutral	$66.14M	―	-130.26%	―	-6.27%	16.76%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%

Electrocore Corporate Events

Electrocore Completes Merger with NeuroMetrix

On May 2, 2025, electroCore, Inc. announced the completion of its merger with NeuroMetrix, Inc., which positions electroCore as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, enhances its commercial reach, particularly within the VA Hospital System, and is expected to significantly increase its addressable market for chronic pain and wellness conditions. As a result of the merger, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, and its shares will be de-listed from the Nasdaq Capital Market.